However, the 3-month treatment HbA1c values were significantly lower (TNF inhibitors 6.1% and TCZ 5.8%, p = 0.010) and the changes in HbA1c (ΔHbA1c) were significantly greater in the TCZ group (TNF inhibitors 0.1% and TCZ 0.4%, p < 0.001), suggesting that TCZ decreases HbA1c levels in RA patients to a greater extent than TNF inhibitors [188]. Here, TNF is linked to rheumatoid arthritis.